Tim Cook

Business

Annaly Capital Posts Strong 2025 Finish, Citing Favorable Markets and Strategic Execution

Annaly Capital Management capped off a robust 2025 with a fourth-quarter economic return of 8.6%, driven by a constructive fixed-income environment and growth across its core strategies. The mortgage REIT highlighted conservative leverage, a secure dividend, and strategic capital deployment as it navigates evolving market conditions.

Jan 30, 2026

Business

Norfolk Southern Navigates Soft Demand, Touts Safety Gains and Cost Discipline in Q4

Despite a weaker-than-expected volume environment, Norfolk Southern reported in-line cost performance for Q4 and highlighted significant strides in operational safety and efficiency. Executives pointed to a pivotal year of structural change while outlining cost and capital expenditure guidance for 2026.

Jan 30, 2026

Business

Altria Navigates Smoke-Free Shift Amid Illicit Vape Headwinds, Posts Steady Growth

Altria Group reported adjusted earnings growth and robust shareholder returns for 2025, even as it grapples with a rapidly transforming nicotine market dominated by illicit flavored vapes and intense competition in oral tobacco.

Jan 30, 2026

Business

Murphy Oil Navigates Price Volatility, Bets Big on Vietnam and Offshore Growth in 2026

Despite a challenging price environment, Murphy Oil (MUR) reported strong operational execution for 2025 and laid out a capital plan focused on funding key international and offshore projects. While near-term production is set to dip, CEO Eric Hambly highlighted a transformative discovery in Vietnam and strategic portfolio expansion as pillars for future growth.

Jan 30, 2026

Business

National Fuel Gas Kicks Off Fiscal 2026 with Strong Upstream Performance, Eyes Pipeline Growth and Ohio Acquisition

National Fuel Gas (NFG) reported robust first-quarter earnings, driven by a 29% surge in upstream EBITDA. Executives highlighted progress on pipeline expansions, strategic hedging against volatile gas prices, and the planned acquisition of CenterPoint's Ohio utility, while reaffirming full-year guidance.

Jan 30, 2026

Business

Meritage Homes Navigates 'Softer' Housing Market, Prioritizes Margins Over Volume

Meritage Homes concluded a challenging 2025, citing affordability pressures and waning buyer confidence. While maintaining a cautious stance on incentives, the homebuilder is expanding its community footprint and boosting shareholder returns, betting on long-term demographic demand.

Jan 30, 2026

Business

Market Turbulence Creates Buying Opportunities: Three European Stocks Trading at a Discount

Amidst a backdrop of geopolitical tensions and market volatility, a closer look reveals resilient European companies whose current share prices may not reflect their underlying strength and future growth prospects.

Jan 30, 2026

Business

Insider Bets Signal Confidence in Select European Growth Stocks Amid Market Uncertainty

As the STOXX Europe 600 stumbles under geopolitical and trade pressures, a focus on companies with significant insider ownership reveals where leadership is putting its own capital on the line. We examine three firms where high insider stakes coincide with robust growth forecasts.

Jan 30, 2026

Business

Seeking Shelter in Dividends: European Stocks Offering Income Amid Market Uncertainty

As volatility returns to European markets, investors are turning to dividend-paying stocks for income and stability. We examine three companies with compelling, yet distinct, dividend profiles for income-focused portfolios.

Jan 30, 2026

Business

KPN's Steady EPS Growth Offers a Haven for Investors Weary of Speculative Tech Bets

As markets swing between hype and fundamentals, Royal KPN's consistent earnings growth and prudent governance present a compelling case for stability-focused investors in the telecom sector.

Jan 30, 2026

Business

Bitcoin Retreats Below $90K as $8.8 Billion Options Expiry Looms, Testing Market Resilience

Bitcoin's struggle to hold the $90,000 level intensifies as a massive monthly options expiry approaches, driving traders toward defensive positioning and heightened volatility hedging.

Jan 30, 2026

Business

Vera Therapeutics Sees Major Price Target Hikes as Analysts Bet Big on Its Kidney Disease Drug

Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.

Jan 30, 2026

Business

CS Disco (LAW) Gains Analyst Backing Amid AI-Driven Growth, But Is It a Buy?

Jefferies raises price target on CS Disco following strong Q3 results fueled by its Cecilia AI platform, yet maintains a cautious 'Hold' rating as the company balances growth investments against profitability.

Jan 30, 2026

Business

Institutional Investors Hold Sway: British Land's 88% Stake Highlights Market Confidence and Risks

British Land Company PLC (LON:BLND) finds itself firmly in the hands of institutional investors, who control 88% of its shares. While this signals strong professional backing, it also raises questions about stock volatility and boardroom influence in the UK's property sector.

Jan 30, 2026

Business

Nuvation Bio's Ibtrozi Gains Favor on Strong Launch, Truist Raises Target

Truist Securities has increased its price target for Nuvation Bio, highlighting the promising early commercial traction of its oncology drug Ibtrozi, which is outpacing competitors in the ROS1 inhibitor space.

Jan 30, 2026

Business

Analysts Trim Targets on Duolingo Amid Questions Over User Growth Sustainability

DA Davidson joins Morgan Stanley in lowering price targets for language-learning app Duolingo, citing data suggesting daily active user growth may fall short of expectations despite a strong start to the year.

Jan 30, 2026

Business

Analysts Bullish on Riot Platforms After Strategic AMD Data Center Deal

Keefe Bruyette & Woods raises its price target on Riot Platforms (RIOT) to $23, citing a new long-term agreement with AMD that provides revenue visibility and supports the company's high-performance computing strategy.

Jan 30, 2026

Business

UBS Bets Big on Biotech Turnaround, Initiates Arcellx Coverage with $100 Target

UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.

Jan 30, 2026

Business

TD Cowen Stands By Alphatec (ATEC) With Buy Rating, Sees $20 Target Amid Coverage Shift

Despite a lowered price target following an analyst transition, TD Cowen maintains a bullish stance on Alphatec Holdings, citing undervalued growth drivers including a new regenerative bone graft partnership and a robust long-term revenue outlook.

Jan 30, 2026

Business

Mineralys Therapeutics Submits New Drug Application for Hypertension Treatment Lorundrostat, Backed by Strong Clinical Data

Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.

Jan 30, 2026